Medical device marketing and advertising materials must follow FDA regulations and guidance, as well as FTC truth-in-advertising requirements. These agencies place strict parameters around what you can and can’t say, the evidence required to support claims, and the delicate balance of benefits and risks.
B2B companies that serve the medical device industry don’t generally have to follow the FDA’s rules around drug and device advertising, but they don’t get a free pass on compliance. If you’re B2B medtech marketing, it’s good practice to follow the same principles enforced by the FDA in addition to truth-in-advertising laws enforced by the FTC.
Most B2B medtech service providers, consultants, and technology vendors that market to medical device manufacturers do follow FDA-adjacent best practices. However, missteps happen more often than you’d think. Those missteps may not trigger an enforcement letter from the FDA, but they could erode customer trust and ding your reputation.
Key Takeaways: What B2B Medtech Marketers Get Wrong (and How to Fix It)
- B2B service providers aren’t subject to FDA device advertising rules—but FTC truth-in-advertising laws still apply
- Device-level outcomes (safety, efficacy, risk reduction) don’t translate cleanly to service-level claims
- Claims about speed, certainty, or regulatory outcomes are risky unless carefully qualified and substantiated
- Case studies should be framed as examples, not guarantees, with clear context
- When language feels “almost right,” it’s worth slowing down—implied claims matter as much as explicit ones
B2B medtech marketing missteps typically fall into these 5 categories:
1. Borrowing device-level outcomes for B2B medtech services
I see this one a lot.
Phrases like “improves patient safety” or “reduces use errors” sneak into copy that relates to human factors, regulatory consulting, or engineering services.
The problem? Those are device outcomes, not service capabilities. Services can support those outcomes, but they can’t claim them outright—at least not without very specific, contextual evidence.
This usually happens because marketing borrows language from product materials without considering or adjusting for context.
What to do instead: Think about what the service provides. Does your human factors team directly improve patient safety? No. Your experts identify areas in device design that can be modified to minimize hazards and promote patient safety.
2. Overpromising speed, certainty, or regulatory outcomes
Versions of the phrases below pop up all over the place:
“Accelerate FDA clearance.”
“Get to market faster.”
“Reduce regulatory risk.”
These phrases pop up all the time in clinical tech content, but from a claims standpoint they’re risky. Service providers and technology vendors do not control FDA decisions, timelines, or outcomes. Unless those claims are carefully qualified, they’re hard to substantiate.
What to do instead: Add supportive language. It may feel less punchy, but it keeps you out of murky water. “We aggregate your data to help you move to regulatory submission sooner.”
If you have the customer data to back up your claims, include a valid statistic. “Move from X to Y up to 50% faster.”* *Footnote with reference citing your study.
3. Treating one case study like universal proof
A single successful project does not equate to “we consistently deliver X.”
Case studies are great—but they must be framed as examples, not guarantees. When you draft your case study, be sure to add relevant context: device type, use environment, development stage, team maturity.
Without that framing, a strong story starts to look like an unqualified claim.
What to do instead: use a proof point or a customer quote from the case study in your marketing materials and link to the full case. Borrowing a principle from medical device advertising, also make sure the case reflects a common scenario. Anomalies can be misleading.
4. Letting sales language override good judgment
Imagine you developed a brochure that strikes the right balance between compelling and accurate. A sales rep pushes back, wanting punchier language. “Can you make it stronger?”
“Stronger” often means broader, faster, or more guaranteed—exactly where risk creeps in.
If you inflate your claims, you end up carrying more risk. It may go unnoticed for a while, but eventually it will make someone uncomfortable.
What to do instead: listen to their feedback. If the suggested revision crosses into crosses into misleading territory under FTC truth-in-advertising standards, give them the 101 on truth-in-advertising laws.
5. Assuming “everyone knows what we mean”
This is a sneaky mistake.
Words like “improves usability” feel safe—but improve how? Compared to what? For which device? Based on what evidence?
Regulators and regulators-at-heart care about how claims could be interpreted, not what the writer intended.
What to do instead: Tell the full story. If you want to say your product or service is better, faster, cheaper, or smarter, make sure you have the data to back it up. If you don’t have any evidence to support your claim (“in theory, it should speed up development…”), better to choose different messaging.
B2B medtech marketing materials aren’t held to the same rules as medical device content, but the principles behind FDA’s thinking still apply. Think clear claims, appropriate evidence, and no implied guarantees.
Credibility is fragile, and once it’s gone, it’s hard to get back.
If your spidey sense tells you a tagline crosses the line, it’s worth listening to that voice.
Need sales and marketing materials that are accurate, credible, and still engaging? Get in touch to discuss your next project.
